Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Healthcare Extenders Can Reduce Physician Burden & Improve Patient Access & Care

Kimberly Steinbarger, PT, MHS, DHSc, & Saba Mohiuddin, PharmD, BCACP  |  Issue: August 2021  |  August 11, 2021

insta_photos / shutterstock.com

insta_photos / shutterstock.com

In the early 1900s, the treatment for rheumatic and musculoskeletal disease (RMD) was primarily targeted at symptomatic relief and included analgesics, physical therapy, splinting and bed rest. With the discovery of methotrexate and its impact on rheumatoid arthritis (RA) management, a much-needed evolution of medications targeting disease activity began.

Over the past 30 years, several med­ications have been added to the armamentarium for rheumatic diseases, starting with medications now considered disease-modifying anti-rheumatic drugs (e.g., sulfasalazine, hydroxychloroquine, methotrexate). With the late 1990s came biologic therapies, including monoclonal antibodies and genetically engineered proteins that target cytokines and cell surface molecules.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This pharmacologic evolution has greatly improved the lives of those with RMD; however, work disability, fatigue and the need for psychosocial support remain concerns. Team-based interventions, including non-pharmacologic, have also emerged as priorities for both patients and provider teams.

Patient and provider opinions differ regarding treatment priorities.2,3 Physicians excel at tracking the number of swollen joints, pain level, labs and global measures, but patients would also like their fatigue, stiffness, self-management, participation, sleep, emotional distress and daily functioning addressed. This is much more than a rheumatologist can address in an office appointment, especially in areas of the country with limited access to specialists.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Enter the healthcare extender.

A holistic approach to caring for patients with RMD goes beyond the medications that help prevent disease progression and damage. It requires a team of practitioners, each with their own expertise, to contribute to an individual’s quality of life.

To help meet the needs of the patient population with RMD, rheumatologists can look to advanced practice providers (APPs), including physical therapists (PTs), occupational therapists (OTs) and pharmacists. Other APPs that rheumatology practices should consider to meet varying patient needs are physician assistants (PAs), nurse practitioners (NPs), dietitians and social workers. Developing relationships with these practitioners early in their disease process can help patients preserve function, reduce pain and increase their ability to participate in activities of daily living.4

PTs

PTs can do much more than help patients with a hot joint to improve function. They can develop individualized physical activity plans for patients and suggest changes patients can make to adapt to the cyclical nature of their disease.

Doctorally prepared PTs are at the forefront of prevention and wellness for those with neuromusculoskeletal conditions and are starting to make inroads into primary healthcare.5 They are important patient advocates in developing accommodation plans in line with the Americans with Disabilities Act. They are experts in non-pharmacological pain management, particularly as it affects mobility, activity, fatigue and sleep.

If PT is the heart of rehabilitation, OT is the soul.

Leisure activities, particularly those involving mobility and physical activity, are relinquished by patients as their disease process takes hold.6 This loss contributes to an overall decrease in quality of life, and can be addressed by PTs. As movement experts, PTs help patients find ways to participate in activities and capture some semblance of their predisease lifestyle.

As PTs move into primary care for neuromusculoskeletal conditions, the importance of an annual PT checkup for some patient populations, such as those with rheumatic disease, becomes clear.7,8

OTs

Patients benefit the most when referred to an OT for early intervention. OTs support patients with learning strategies to preserve engagement in valued occupations. As the name suggests, OTs can dive into patients’ lives and walk beside them as they figure out how to adapt their occupations or life roles and activities to accommodate their new diagnosis and/or changes in symptoms or disease processes.

Activities and roles OTs can assist with include work and school, household management, leisure activity, parenthood, social roles and civic responsibilities.9 Interventions include, but are not limited to, energy conservation; management of fatigue, cognitive deficits and psycho­social health; activity and environmental modifications; and orthoses to protect painful or unstable joints, especially in the hands.

OTs work closely with PTs, as each focus complements, but does not repeat, the work of the other. If PT is the heart of rehabilitation, OT is the soul.

A Pharmacist Assist

Embedding a clinical pharmacist within the rheumatology clinic can have a positive impact on patient care. Pharmacists in this role typically complete one or two years of post-graduate residency training after completing a Doctor of Pharmacy degree program.

Clinical pharmacists can counsel patients on new medications and have extensive discussions on risks vs. benefits. This frees up the rheumatologist’s time to focus on diagnosis, disease progression and prognosis.

Pharmacist appointments are typically completed after the initial discussion with the rheumatologist, allowing for an extended conversation focused on appropriate prescreening, medication management, infection risk prevention through vaccine, etc.

Clinical pharmacists can practice under a collaborative practice agreement with physicians that authorizes them to order and titrate medications, order laboratory testing and co-manage patients’ chronic diseases. For example, a newly diagnosed patient with RA starting on methotrexate may have monthly follow-up appointments with the clinical pharmacist, who can assess medication safety and make titrations as needed for efficacy and side-effect management. This collaboration can reduce physician burden, providing an opportunity for the rheumatologist to see additional patients, and improve patient access and quality of care. Clinical pharmacists can serve as medication experts, providing education and assistance with complex medication questions, conducting literature reviews and assisting with barriers to medication access.

In Sum

Since the 1990s, the pool of healthcare providers serving as APPs has evolved beyond the traditional model of NPs and PAs to include PTs, OTs, pharmacists and other healthcare providers, such as social workers and dietitians. Patient-centered holistic care for complex diseases takes a village. Early intervention and consultation with the entire care team can significantly impact the RMD management process, improving the patient’s quality of life and the rheumatologist’s practice.


Kimberly Steinbarger, PT, MHS, DHScKimberly Steinbarger, PT, MHS, DHSc, is a physical therapist, an individual with rheumatoid arthritis and the director of clinical education for the School of Physical Therapy, Husson University, Bangor, Maine.

Saba Mohiuddin, PharmD, BCACPSaba Mohiuddin, PharmD, BCACP, is the rheumatology clinical pharmacy specialist at Cleveland Clinic, Department of Rheumatic and Immunologic Disease, Ohio.

References

  1. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology. 2012 Dec;51(suppl 6):vi28–vi36.
  2. Bartlett SJ, Hewlett S, Bingham CO, et al. Identifying core domains to assess flare in rheumatoid arthritis: An OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012 Nov;71(11):1855–1860.
  3. Dures E, Almeida C, Caesley J, et al. Patient preferences for psychological support in inflammatory arthritis: A multicentre survey. Ann Rheum Dis. 2016 Jan;75(1):142–147.
  4. Management of early rheumatoid arthritis. Scottish Intercollegiate Guide­lines Network. 2011 Feb.
  5. Bornhöft L, Larsson MEH, Nordeman L, et al. Health effects of direct triaging to physiotherapists in primary care for patients with musculoskeletal disorders: A pragmatic randomized controlled trial. Ther Adv Musculoskelet Dis. 2019 Feb 15;11:1759720X19827504.
  6. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2013–2015. MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):246–253.
  7. Ries E. A deepening footprint. American Physical Therapy Association. 2018 Dec 1.
  8. Annual physical therapy visit. American Physical Therapy Association.
  9. Queiroz de Almeida PHT, Pontes TB, Matheus JPC, et al. [Occupational therapy in rheumatoid arthritis: What rheumatologists need to know.] Rev Bras Reumatol. 2015 May–Jun;55(3):272–280.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:Interprofessional PerspectiveWorkforce Tagged with:Advanced Practice CliniciansAssociation of Rheumatology Professionals (ARP)dietitiannurse practitioneroccupational therapistspharmacistphysical therapistphysician assistantssocial worker

Related Articles

    What Physical & Occupational Therapists Wish Rheumatologists Knew

    June 17, 2019

    Kim Steinbarger, PT, MHS, knows how physical and occupational therapy can make a difference for patients with rheumatic diseases. Ms. Steinbarger was just two years into her career as a physical therapist (PT) when she was diagnosed with rheumatoid arthritis (RA) in 1991. “I’ve seen how regular exercise serves as an important tool in managing…

    Essential Collaboration: Rheumatologists & PTs Must Work Together

    July 14, 2017

    The importance of rheumatologists and physical therapists (PTs) working together for patients cannot be understated. Carol Oatis, PT, PhD, says, “Rheumatologists and PTs have very similar goals. … Collaboration is essential for optimal outcomes.”…

    Medium-sized blood vessels are seen in the dermis and at the dermal-subcutaneous junction. The black arrow identifies a venule, and the blue arrow points to a fibrin deposition in the vessel wall. Extravasated neutrophils and erythrocytes are seen in the interstitium.

    Case Report: A Polyarteritis Nodosa Conundrum

    March 14, 2022

    Figure 1: Lower Extremity Ulceration Varying stages of ulceration are seen on the left (L) and right (R) lower extremities. An eschar formation is on the left (red arrow), and a superficial ulceration is on the right (black arrow). Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries. The clinical…

    What Pharmacists Want Rheumatologists to Know

    May 18, 2019

    Jacob Lund / shutterstock.com Involving pharmacists in the management of chronic diseases benefits patients, says Wendy Ramey, BSPharm, RPh, CSP, a clinical pharmacy specialist in rheumatology at the University of Kentucky, Lexington. She knows this personally. As someone with rheumatoid arthritis (RA), Ms. Ramey knows pharmacists can play an important role in patient education and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences